Paper Details

  1. Home
  2. Paper Details

Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial.

Author: JiangLan-Lan, LiFeng-Fei, MaJian-Hua, SuXiao-Fei, WuJin-Dan, YanReng-Na, YeLei, ZhangDan-Feng, ZhouPei-Hua, ZhuHong-Hong

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This single-center, randomized, control, open-labeled trial investigated whether saxagliptin add-on therapy to continuous subcutaneous insulin infusion (CSII) further improves blood glycemic control in patients with newly diagnosed type 2 diabetes (T2D). After 4-week therapy, patients with saxagliptin add-on therapy exhibited further improvement of mean amplitude glycemic excursion (MAGE) compared with the control group.
Paper Details　
Original Abstract of the Article :
BACKGROUND: To investigate whether saxagliptin add-on therapy to continuous subcutaneous insulin infusion (CSII) further improve blood glycemic control than CSII therapy in patients with newly diagnosed type 2 diabetes (T2D). METHODS: This was a single-center, randomized, control, open-labeled tria...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089116/

データ提供：米国国立医学図書館（NLM）

Saxagliptin Add-on Therapy for Improved Blood Sugar Control

Type 2 diabetes (T2D) is a chronic metabolic disorder characterized by high blood sugar levels. This study, published in Diabetes Research and Clinical Practice, investigated the effects of saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, when added to continuous subcutaneous insulin infusion (CSII) therapy in newly diagnosed T2D patients.

Saxagliptin Improves Glycemic Control

The study found that saxagliptin add-on therapy to CSII further improved blood glucose control in patients with T2D. This included reduced blood glucose fluctuations, improved mean amplitude glycemic excursion (MAGE), and lower insulin doses required for euglycemic control. Furthermore, the saxagliptin group experienced significantly lower blood glucose levels during overnight hours.

Addressing Blood Sugar Management in T2D

This study highlights the potential benefits of saxagliptin as an add-on therapy for improving glycemic control in patients with T2D. It emphasizes the importance of individualized treatment approaches to effectively manage blood sugar levels and minimize complications associated with T2D.

Dr.Camel's Conclusion

Managing type 2 diabetes is like navigating a shifting sand dune, requiring careful attention to blood sugar levels. This study suggests that saxagliptin, like a well-placed oasis, can help improve blood sugar control. By adding this medication to insulin therapy, patients may be able to achieve better blood sugar management and potentially improve their overall health.
Date :
  1. Date Completed 2017-02-09
  2. Date Revised 2021-01-09
Further Info :

Pubmed ID

27787387

DOI: Digital Object Identifier

PMC5089116

Related Literature

Article Analysis
・Effects of saxagliptin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.